Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feladilimab + Tremelimumab in Advanced Solid Tumors
NCT03693612Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2018
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of feladilimab in head and neck squamous cell carcinoma (HNSCC), cutaneous melanoma (CM), non-small cell lung cancer (NSCLC) and 4 more (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Dose Limiting Toxicities up to 28 days, Number of Participants With Adverse Events, Serious Adverse Events and Adverse Events of Special Interest up to 4 years and 1 more. Started Nov 2018; status: completed.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)cutaneous melanoma (CM)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03693612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693612.